Syros

Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, NASDAQ, Safety, Government, AACR, Clinical trial, American Association for Cancer Research, Twitter, Private Securities Litigation Reform Act, CDK12, Workforce, U.S. Securities and Exchange Commission, Acute promyelocytic leukemia, Annual report, Compte rendu, Genome, DNA, RARA, CDK7, Patient, Security (finance), Acute myeloid leukemia, American Association, Gene, COVID-19, Syros, Lymphatic system, Freedom, Association, Program, Arsenic trioxide, LinkedIn, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.
  • The online-only e-poster will include data that show Syros orally available, selective CDK12 inhibitor has potent single agent activity in vitro and in vivo in multiple cancer models as well as enhanced antitumor effect in combination with DNA damaging agents.
  • These data support Syros plans to nominate a development candidate from its CDK12 inhibitor program in the second half of 2022.
  • Details of the e-poster presentation are as follows:
    The abstract is now available on the AACR conference website: https://www.aacr.org/meeting/aacr-annual-meeting-2022/ .

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 1, 2022
Keck School of Medicine of USC, Private Securities Litigation Reform Act, Dartmouth College, Patient, Entinostat, Medical director, Food and Drug Administration, Industry, Forward-looking statement, Twitter, Food, Syros, U.S. Securities and Exchange Commission, Safety, Rady Children's Hospital, Drug, University, LinkedIn, Medicine, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Company, COVID-19, Alnylam Pharmaceuticals, Risk, Investigational New Drug, University of California, HDAC, Degenerative disease, Pharmaceutical industry, Research, Biogen

WALTHAM, Mass., March 1, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately.

Key Points: 
  • WALTHAM, Mass., March 1, 2022 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately.
  • Her appointment is the result of a thorough succession planning process as we lay the groundwork for our evolution into a fully-integrated oncology company.
  • Prior to joining Syros, she served as Senior Medical Director at Alnylam Pharmaceuticals, and was a Medical Director in Biogen's Rare Disease Innovation Unit.
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Syros to Participate in Upcoming Virtual Investor Conferences in March

Retrieved on: 
Monday, February 28, 2022
FDA, Pharmaceutical, Health, Clinical Trials, Investor, Webcast, Twitter, NASDAQ, Gene, RARA, CDK7, Genome, Arsenic trioxide, Syros, Lymphatic system, Acute myeloid leukemia, LinkedIn, Acute promyelocytic leukemia, Patient, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March.
  • Details are as follows:
    To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com .
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS

Retrieved on: 
Wednesday, February 2, 2022
FDA, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Safety, Acute myeloid leukemia, Government, Patient, Myelodysplastic syndrome, Food, NASDAQ, Lymphatic system, CDK7, Clinical trial, MDS, Acute promyelocytic leukemia, ODD, Twitter, COVID-19, Population, Syros, Arsenic trioxide, Workforce, U.S. Securities and Exchange Commission, Gene, Annual report, Freedom, Compte rendu, RARA, Genome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Azacitidine, FDA, Security (finance), LinkedIn, AML, Degenerative disease, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS).

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS).
  • The FDAs orphan drug designation is an important milestone in the development of tamibarotene as a treatment for MDS, said David A. Roth, M.D., Syros Chief Medical Officer.
  • Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.
  • Syros is also evaluating tamibarotene in combination with azacitidine and venetoclax for RARA-positive patients with newly diagnosed unfit acute myeloid leukemia (AML), for which tamibarotene had previously received orphan drug designation.

Genesys Spine is pleased to announce a record year for their SI Joint Division

Retrieved on: 
Tuesday, January 18, 2022
Syros, Cervical, Spine, SI, Growth, Joint, MD, Radiology, Genesys, 3D printing

AUSTIN, Texas, Jan. 18, 2022 /PRNewswire/ --Genesys Spine, a medical device manufacturer based in Austin, Texas, announced today that their SI Joint division exceeded 2021 sales targets: a 184% growth over 2020.

Key Points: 
  • AUSTIN, Texas, Jan. 18, 2022 /PRNewswire/ --Genesys Spine, a medical device manufacturer based in Austin, Texas, announced today that their SI Joint division exceeded 2021 sales targets: a 184% growth over 2020.
  • "said Meredith Gavlick, Chief Strategy Officer, SI Fusion
    The Genesys Spine SI joint fusion system includes comprehensive options for Posterior, Lateral and Hybrid surgical approaches.
  • The lateral and hybrid procedures include the SIros 3-D printed implants which provide optimal stabilization of the SI joint through lateral access and treatment at the SI joint with the aid of compressive implants.
  • For more info on the Genesys Spine SI Joint Fusion System, Thoracolumbar or Cervical suite of products please visit www.genesysspine.com .

Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Monday, January 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Clinical trial, Acute myeloid leukemia, APL, Safety, CDK12, Freedom, Compte rendu, Gene, Growth, Lymphoma, LinkedIn, WRN, Security (finance), Patient, Azacitidine, Genome, Type, NASDAQ, ATO, Mantle cell lymphoma, BRAF, U.S. Securities and Exchange Commission, NDA, Workforce, Annual report, CDK7, Syros, Pancreatic cancer, AML, Food, Acute promyelocytic leukemia, CRC, Private Securities Litigation Reform Act, Arsenic trioxide, Company, Lymphatic system, Feedback, RARA, CDK, FDA, COVID-19, Government, Twitter, Hematological Cancer Research Investment and Education Act, FOLFIRINOX, IV, Hematology, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PK, Roche, Fine chemical, Pharmaceutical industry

2022 promises to be a transformative year as we continue to advance our studies of tamibarotene, SY-2101, and SY-5609.

Key Points: 
  • 2022 promises to be a transformative year as we continue to advance our studies of tamibarotene, SY-2101, and SY-5609.
  • Together, we believe these upcoming milestones will provide insight into the clinical potential of our development-stage assets and lay the foundation for our long-term growth as we advance Syros into a fully integrated biopharmaceutical company.
  • We are excited to be the first company to advance a CDK7 inhibitor into hematology clinical development.
  • Syros is also evaluating tamibarotene for the treatment of patients with RARA-positive newly diagnosed unfit acute myeloid leukemia (AML).

Syros to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Syros, Investor, Lymphatic system, NASDAQ, Gene, Acute myeloid leukemia, RARA, Twitter, Genome, CDK7, LinkedIn, Acute promyelocytic leukemia, Webcast, Patient, Arsenic trioxide, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences.
  • Presentation Time: A pre-recorded fireside chat will be made available on-demand beginning at 10:00 a.m.
  • ET
    To access the webcasts and subsequent archived recording of each fireside chat, please visit the Investors & Media section of the Syros website at www.syros.com .
  • Syros is redefining the power of small molecules to control the expression of genes.

Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, November 5, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Genetics, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Safety, Syros, G&A, Private Securities Litigation Reform Act, Investor, Director, Venetoclax, Leadership, Clinical trial, Government, Lymphatic system, Security (finance), Initiate, Congress, Compte rendu, Roche, Gene, Acute myeloid leukemia, Freedom, COVID-19, Workforce, GBT, ID, Annual report, BTK, RARA, Twitter, Mantle cell lymphoma, Board, APL, U.S. Securities and Exchange Commission, Research, Genome, Azacitidine, CDK7, LinkedIn, SD, Acute promyelocytic leukemia, BRAF, Pharmacokinetics, Webcast, Pancreatic cancer, Marketing, Patient, Arsenic trioxide, Medical device, Pharmaceutical industry, Medical imaging

Initiate expansion cohort of our SY-5609 trial in combination with chemotherapy in second-line pancreatic cancer in the fourth quarter of 2021.

Key Points: 
  • Initiate expansion cohort of our SY-5609 trial in combination with chemotherapy in second-line pancreatic cancer in the fourth quarter of 2021.
  • Research and development expenses were $27.3 million for the third quarter of 2021, as compared to $17.7 million for the third quarter of 2020.
  • General and administrative (G&A) expenses were $5.3 million for the third quarter of 2021, as compared to $5.2 million for the third quarter of 2020.
  • ET to discuss third quarter 2021 financial results and provide a corporate update.

Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021

Retrieved on: 
Friday, October 29, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, LinkedIn, Gene, Genome, RARA, Twitter, Patient, NASDAQ, Investor, Acute promyelocytic leukemia, ID, Lymphatic system, Webcast, Acute myeloid leukemia, Arsenic trioxide, CDK7, Syros, Pharmaceutical industry

ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a corporate update.
  • To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 3287324.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .
  • Syros is redefining the power of small molecules to control the expression of genes.

Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, October 13, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Acute promyelocytic leukemia, CDK7, Genome, Syros, Nasdaq, Gene, Director, Employment, RARA, Lymphatic system, Patient, Company, Acute myeloid leukemia, Arsenic trioxide, Letter, Pharmaceutical industry

Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Companys recently hired Chief Financial Officer, in accordance with Mr. Haass employment offer letter.

Key Points: 
  • Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Companys recently hired Chief Financial Officer, in accordance with Mr. Haass employment offer letter.
  • The grant was approved by the Companys Board of Directors and was made as a material inducement to Mr. Haass acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.
  • The inducement stock option award is subject to the terms and conditions of the inducement stock option award agreement covering the grant of the inducement stock options.
  • Syros is redefining the power of small molecules to control the expression of genes.